Clinical Trial

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-11.
Trial Details
NCT Number NCT07472413
Lead Sponsor University of Miami
Conditions Multiple Sclerosis
Enrollment 60 participants
Start Date 2026-09-01
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-13